PCI Biotech to present at DNB Nordic Healthcare Conference 2021
December 14, 2021 05:45 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 14 December 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech: Independent Data Monitoring Committee recommends continuation of two treatments in the RELEASE trial
December 13, 2021 11:12 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 13 December 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the Independent Data Monitoring Committee (IDMC) has reviewed the safety...
PCI Biotech: Update on regulatory interactions for the RELEASE trial
December 07, 2021 12:45 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 7 December 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the company has concluded on the interactions with regulatory authorities in...
PCI Biotech and Immunicum Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments
November 30, 2021 02:00 ET
|
PCI Biotech Holding ASA
Oslo, Norway, November 30, 2021 - PCI Biotech Holding ASA (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via Photochemical Internalisation and...
PCI Biotech to present at ABGSC Nordic Rare Disease Seminar
November 29, 2021 05:07 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 29 November 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech Q3 2021 interim results
November 17, 2021 01:00 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 17 November 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim Q3 2021 results. Please find enclosed the report and presentation. ...
PCI Biotech: Invitation to Q3 2021 result presentation
November 09, 2021 06:50 ET
|
PCI Biotech Holding ASA
Oslo, Norway, 9 November 2021 - PCI Biotech (OSE: PCIB) invites to a presentation of the company's Q3 2021 results on Wednesday 17 November 2021 at Oslo Cancer Cluster Innovation Park. Time:...
PCI Biotech to present at the 9th International mRNA Health Conference
November 09, 2021 03:30 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 9 November 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced...
PCI Biotech: Presentation of fimaChem for bile duct cancer at IPA masterclass series
November 08, 2021 05:15 ET
|
PCI Biotech Holding ASA
Oslo (Norway), 8 November 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the coordinating principal investigator for the RELEASE trial, Prof. Dr. Jörg...
PCI Biotech: Employee share option scheme
September 06, 2021 12:20 ET
|
PCI Biotech Holding ASA
Oslo, 6 September 2021 In accordance with the authorisation granted and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech...